Inclusion Criteria:

          -  Patients must have histologically confirmed uterine corpus serous adenocarcinoma

          -  Patients must be planned for surgical hysterectomy and operative staging

          -  Patients must have adequate archival tissue less than 6 weeks old or have sufficient
             tumor tissue and be willing to undergo an endometrial pipelle biopsy prior to
             beginning study treatment

          -  Patients must have adequate primary tumor volume, as determined by imaging (e.g.,
             computed tomography [CT], ultrasound, magnetic resonance imaging [MRI]) at eligibility
             screening, to accommodate research specimen collections in addition to clinical
             pathology evaluation

          -  Patients must not have received any prior anticancer treatment for endometrial cancer

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =<
             2 (Karnofsky >= 60%)

          -  Absolute neutrophil count >= 1,000/mcL

          -  Platelets >= 100,000/mcL

          -  Hemoglobin >= 9.0 g/dL

          -  Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =< 3 x institutional ULN

          -  International normalized ratio (INR) =< 2

          -  Creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 60
             mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function
             values, no lower than 30 mL/min/1.73 m^2

          -  Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
             therapy with undetectable viral load within 6 months are eligible for this trial

          -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral
             load must be undetectable on suppressive therapy, if indicated

          -  Patients with a history of hepatitis C virus (HCV) infection must have been treated
             and cured. For patients with HCV infection who are currently on treatment, they are
             eligible if they have an undetectable HCV viral load

          -  Patients with a prior or concurrent malignancy whose natural history or treatment does
             not have the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial

          -  Patients with known history or current symptoms of cardiac disease, or history of
             treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
             function using the New York Heart Association Functional Classification. To be
             eligible for this trial, patients should be class 2B or better

          -  Patients of childbearing potential must have a negative pregnancy test result prior to
             beginning study treatment

          -  Ability to understand and the willingness to sign a written informed consent document.
             Participants with impaired decision-making capacity (IDMC) are not eligible as there
             is limited likelihood of direct benefit for participants in this study

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study

          -  Patients who have not recovered from adverse events due to prior anti-cancer therapy
             (i.e., have residual toxicities > grade 1) with the exception of alopecia

          -  Patients who are receiving any other investigational agents

          -  Patients who have known brain metastases, as they are not candidates for surgery

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to triapine

          -  Patients receiving any medications or substances that are inhibitors or inducers of
             triapine, as well as medications known to be associated with methemoglobinemia, are
             ineligible. Triapine drug interactions have not yet been identified. As part of the
             enrollment/informed consent procedures, the patient will be counseled on the risk of
             interactions with other agents, and what to do if new medications need to be
             prescribed or if the patient is considering a new over-the-counter medicine or herbal
             product

          -  Patients with uncontrolled intercurrent illness

          -  Patients with psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are not eligible.
             Patients at risk for G6PD deficiency must be screened prior to enrollment